Clinical trial · Interventional
Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma
Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine (or FET), a New Tracer PET (Positron Emission Tomography) , in the Diagnosis of Low Grade Glioma
NCT02286531CI-TRIAL-00018872PET-FETIIcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Determine the overall discriminatory ability of FET PET in the diagnosis of glioma grade II (referring to the current diagnostic gold standard represented by the histopathology exam of a tumor sample).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low Grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| O-(2[18F]FLUOROETHYL)-L-TYROSINE | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FET imaging
- description
- FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2\[18F\]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
- interventionNames
- Drug: O-(2[18F]FLUOROETHYL)-L-TYROSINE
Primary outcomes (1)
- measure
- Determine the overall discriminating capacity of FET-PET in the diagnosis of glioma grade II (referring to current diagnostic gold standard represented by the histopathological examination of a tumor sample).
- timeFrame
- TEP and MRI Imagy 1 month before surgery
Secondary outcomes (3)
- measure
- - Determine the threshold with the highest positive likelihood ratio. - Determine the threshold with the highest positive likelihood ratio.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients over 18 years * Diagnosis of glioma grade II referred on clinical and MRI morphologic * Realization of a brain MRI in preoperative condition of neuronavigation (MRI sequences including axial T2, Flair, T1, T1 with gadolinium) in a within 1 month with FET PET. * Histological examination scheduled within one month with FET PET by resection (complete or partial) or by biopsy * Patients who signed informed consent * No against-indication for PET * No against-indications to MRI Exclusion Criteria: * Grade II glioma who have received specific treatment with radiotherapy and or chemotherapy. * Pregnant or breastfeeding women. * Weight greater than 120 Kg * against-indication to PET * against- indication gadolinium * Possible side effects to MRI (magnetic foreign bodies, pacemaker, congestive severe renal).) * Patient under guardianship * No coverage by social security
References
Publications (0)
Data not yet available
No reference posted for this study.